JP2017537080A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537080A5 JP2017537080A5 JP2017524447A JP2017524447A JP2017537080A5 JP 2017537080 A5 JP2017537080 A5 JP 2017537080A5 JP 2017524447 A JP2017524447 A JP 2017524447A JP 2017524447 A JP2017524447 A JP 2017524447A JP 2017537080 A5 JP2017537080 A5 JP 2017537080A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- cancer
- compound
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- -1 substituted Chemical class 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 1
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462075671P | 2014-11-05 | 2014-11-05 | |
| US62/075,671 | 2014-11-05 | ||
| US201462098022P | 2014-12-30 | 2014-12-30 | |
| US62/098,022 | 2014-12-30 | ||
| PCT/US2015/059311 WO2016073770A1 (en) | 2014-11-05 | 2015-11-05 | Immunoregulatory agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537080A JP2017537080A (ja) | 2017-12-14 |
| JP2017537080A5 true JP2017537080A5 (enExample) | 2018-11-22 |
| JP6735274B2 JP6735274B2 (ja) | 2020-08-05 |
Family
ID=55909825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017524447A Active JP6735274B2 (ja) | 2014-11-05 | 2015-11-05 | 免疫調節剤 |
Country Status (32)
Families Citing this family (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013010099B1 (pt) | 2010-10-26 | 2021-08-10 | Mars, Incorporated | Boronatos como inibidores de arginase |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| WO2015188085A1 (en) | 2014-06-06 | 2015-12-10 | Flexus Biosciences, Inc. | Immunoregulatory agents |
| UY36391A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| WO2016073738A2 (en) | 2014-11-05 | 2016-05-12 | Flexus Biosciences, Inc. | Immunoregulatory agents |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| KR20180069903A (ko) * | 2015-11-02 | 2018-06-25 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩타이드 및 이들의 암 치료에서의 용도 |
| MY196319A (en) | 2015-12-17 | 2023-03-24 | Merck Patent Gmbh | Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders |
| US10696648B2 (en) | 2016-05-04 | 2020-06-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| WO2017192813A1 (en) * | 2016-05-04 | 2017-11-09 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| WO2017192840A1 (en) | 2016-05-04 | 2017-11-09 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| KR20190003687A (ko) | 2016-05-04 | 2019-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법 |
| EP3487516A1 (en) * | 2016-07-19 | 2019-05-29 | Bristol-Myers Squibb Company | Radioligands for imaging the ido1 enzyme |
| WO2018024188A1 (zh) * | 2016-08-02 | 2018-02-08 | 上海迪诺医药科技有限公司 | 多环化合物、其制备方法、药物组合物及应用 |
| CN107674029A (zh) * | 2016-08-02 | 2018-02-09 | 上海迪诺医药科技有限公司 | 多环化合物、其药物组合物及应用 |
| CN109563075B (zh) * | 2016-08-08 | 2022-09-30 | 默克专利股份公司 | Tlr7/8拮抗剂及其用途 |
| CN109843322A (zh) | 2016-08-26 | 2019-06-04 | 百时美施贵宝公司 | 吲哚胺2,3-双加氧酶的抑制剂及其使用方法 |
| MA46093A (fr) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Composés modulateurs du recepteur de type toll |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| US10882856B2 (en) | 2016-09-24 | 2021-01-05 | Beigene, Ltd. | 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases |
| IL265800B2 (en) | 2016-10-11 | 2023-10-01 | Agenus Inc | Anti-LAG-3 antibodies and methods of using them |
| FI3526323T3 (fi) | 2016-10-14 | 2023-06-06 | Prec Biosciences Inc | Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja |
| ES2881395T3 (es) | 2016-12-22 | 2021-11-29 | Calithera Biosciences Inc | Composiciones y métodos para inhibir la actividad de la arginasa |
| EP3570832A4 (en) | 2017-01-17 | 2020-06-10 | Board Of Regents, The University Of Texas System | COMPOUNDS AS INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE AND / OR TRYPTOPHANE-DIOXYGENASE |
| TW202510891A (zh) | 2017-01-31 | 2025-03-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| US11066392B2 (en) | 2017-05-12 | 2021-07-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| SG11201911937UA (en) * | 2017-06-30 | 2020-01-30 | Bristol Myers Squibb Co | Amorphous and crystalline forms of ido inhibitors |
| US11236048B2 (en) | 2017-06-30 | 2022-02-01 | Bristol-Myers Squibb Company | Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation |
| ES2902799T3 (es) | 2017-08-17 | 2022-03-29 | Idorsia Pharmaceuticals Ltd | Inhibidores de indoleamina 2,3-dioxigenasa y/o de triptófano 2,3-dioxigenasa |
| JP7548814B2 (ja) * | 2017-09-20 | 2024-09-10 | ハンジョウ イノゲート ファーマ カンパニー リミテッド | Ｉｄｏ阻害剤および／またはｉｄｏ－ｈｄａｃ二重阻害剤としての多環式化合物 |
| US11351163B2 (en) | 2017-09-29 | 2022-06-07 | Bristol-Myers Squibb Company | Compositions and methods of treating cancer |
| WO2019074822A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE |
| WO2019074824A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE |
| US11180497B2 (en) | 2017-10-18 | 2021-11-23 | Angex Pharmaceutical, Inc. | Cyclic compounds as immunomodulating agents |
| WO2019087028A1 (en) * | 2017-10-30 | 2019-05-09 | Glaxosmithkline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| BR112020010964A2 (pt) * | 2017-12-05 | 2020-11-17 | Glaxosmithkline Intellectual Property Development Limited | moduladores da indolamina 2,3-dioxigenase |
| CN109928922A (zh) * | 2017-12-18 | 2019-06-25 | 成都华健未来科技有限公司 | 一类环己烷类化合物 |
| CN109928924A (zh) * | 2017-12-18 | 2019-06-25 | 成都华健未来科技有限公司 | 一类作为ido抑制剂 |
| CN109928923A (zh) * | 2017-12-18 | 2019-06-25 | 成都华健未来科技有限公司 | 一类作为ido抑制剂化合物 |
| CN109928921A (zh) * | 2017-12-18 | 2019-06-25 | 成都华健未来科技有限公司 | Ido抑制剂 |
| CN109928916A (zh) * | 2017-12-18 | 2019-06-25 | 成都华健未来科技有限公司 | 一类作为ido抑制剂的喹啉-4-基环己烷类化合物 |
| KR102492115B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 2'3' 사이클릭 다이뉴클레오티드 |
| CA3084569A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN109956929B (zh) * | 2017-12-22 | 2023-09-19 | 上海迪诺医药科技有限公司 | 杂环衍生物、其制备方法、药物组合物及应用 |
| CN109956937A (zh) * | 2017-12-22 | 2019-07-02 | 上海海雁医药科技有限公司 | N-(2-环己基乙基)甲酰胺衍生物、其制法与医药上的用途 |
| CN109575022B (zh) * | 2017-12-25 | 2021-09-21 | 成都海博锐药业有限公司 | 一种化合物及其用途 |
| CN109574988B (zh) * | 2017-12-25 | 2022-01-25 | 成都海博锐药业有限公司 | 一种化合物及其用途 |
| CN111471010B (zh) * | 2017-12-29 | 2021-09-28 | 杭州阿诺生物医药科技有限公司 | 吲哚胺-2,3-双加氧酶(ido)抑制剂的制备方法 |
| GB2583606C (en) * | 2017-12-29 | 2021-10-27 | Adlai Nortye Biopharma Co Ltd | Indoleamine 2,3-Dioxygenase inhibitors and use of same in medicine |
| WO2019136112A1 (en) | 2018-01-05 | 2019-07-11 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| ES2907282T3 (es) | 2018-01-15 | 2022-04-22 | Idorsia Pharmaceuticals Ltd | Inhibidores de la indoleamina 2,3-dioxigenasa y/o de la triptófano dioxigenasa |
| CN111247119B (zh) * | 2018-01-19 | 2023-02-03 | 四川科伦博泰生物医药股份有限公司 | 脒类和胍类衍生物、其制备方法及其在医药上的应用 |
| CN110092750B (zh) * | 2018-01-29 | 2023-07-21 | 北京诺诚健华医药科技有限公司 | 五氟硫烷基取代的酰胺类化合物、其制备方法及其在医药学上的应用 |
| WO2019154380A1 (zh) * | 2018-02-11 | 2019-08-15 | 南京明德新药研发股份有限公司 | 犬尿氨酸通路抑制剂 |
| EP4227302A1 (en) | 2018-02-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| AU2019232437A1 (en) | 2018-03-07 | 2020-10-08 | Bayer Aktiengesellschaft | Identification and use of ERK5 inhibitors |
| CN117185987A (zh) * | 2018-03-19 | 2023-12-08 | 四川科伦博泰生物医药股份有限公司 | 脒类和胍类衍生物、其制备方法及其在医药上的应用 |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| CN110357813A (zh) * | 2018-04-09 | 2019-10-22 | 信达生物制药(苏州)有限公司 | 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| AU2019255196A1 (en) * | 2018-04-16 | 2020-11-12 | Arrys Therapeutics, Inc. | EP4 inhibitors and use thereof |
| US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| CN110526898A (zh) | 2018-05-25 | 2019-12-03 | 北京诺诚健华医药科技有限公司 | 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用 |
| CN110105275B (zh) * | 2018-05-28 | 2020-12-29 | 上海海雁医药科技有限公司 | 酰胺类衍生物、其制法与医药上的用途 |
| US11267786B2 (en) * | 2018-06-01 | 2022-03-08 | Merck Sharp & Dohme Corp. | [3.3.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors |
| CN110869351B (zh) * | 2018-06-27 | 2022-03-18 | 深圳仁泰医药科技有限公司 | (r)-n-(4-氯苯基)-2-(顺-4-(6-氟喹啉-4-基)环己基)丙酰胺的晶型 |
| UA126421C2 (uk) | 2018-07-13 | 2022-09-28 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
| US11046649B2 (en) | 2018-07-17 | 2021-06-29 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| US12059420B2 (en) | 2018-07-23 | 2024-08-13 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US12145927B2 (en) | 2018-07-23 | 2024-11-19 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| US11253525B2 (en) | 2018-08-29 | 2022-02-22 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US10959986B2 (en) | 2018-08-29 | 2021-03-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| KR102833434B1 (ko) * | 2018-09-27 | 2025-07-15 | 쉔젠 칩스크린 바이오사이언스 씨오., 엘티디. | 인돌아민-2,3-디옥시게나아제 억제 활성을 갖는 퀴놀린 유도체 |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| HRP20240541T1 (hr) | 2018-10-31 | 2024-07-05 | Gilead Sciences, Inc. | Supstituirani spojevi 6-azabenzimidazola kao inhibitori hpk1 |
| US12139551B2 (en) | 2018-12-03 | 2024-11-12 | Bristol-Myers Squibb Company | Anti-IDO antibody and uses thereof |
| CN112384502B (zh) * | 2019-01-16 | 2022-11-08 | 上海海雁医药科技有限公司 | 环烷基取代的酰胺类衍生物、其制法与医药上的用途 |
| EP3935066A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| US12318403B2 (en) | 2019-03-07 | 2025-06-03 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| BR112021026376A2 (pt) | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | Proteínas de fusão flt3l-fc e métodos de uso |
| CN114127066A (zh) | 2019-07-11 | 2022-03-01 | 爱杜西亚药品有限公司 | 吲哚胺2,3-双加氧酶和/或色氨酸2,3-双加氧酶的抑制剂 |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| BR112022004220A2 (pt) | 2019-09-11 | 2022-05-31 | Bristol Myers Squibb Co | Formulações famacêuticas de inibidores de indoleamina 2, 3-dioxigenase |
| CA3152263A1 (en) | 2019-09-25 | 2021-04-01 | Julia SANTUCCI PEREIRA DEL BUONO | Composite biomarker for cancer therapy |
| JP7398556B2 (ja) | 2019-09-30 | 2023-12-14 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖワクチン及びｈｂｖを治療する方法 |
| CN114901300A (zh) * | 2019-11-12 | 2022-08-12 | 艾迪菲斯健康有限公司 | 用于免疫疗法的精准医学方法 |
| MX2022006134A (es) | 2019-11-26 | 2022-06-17 | Bristol Myers Squibb Co | Sales/cocristales de (r)-n-(4-clorofenil)-2-((1s,4s)-4-(6-fluoroqu inolin-4-il)ciclohexil)propanamida. |
| WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| HRP20251374T1 (hr) | 2020-08-07 | 2025-12-19 | Gilead Sciences, Inc. | Prolijekovi nukleotidnih analoga fosfonamida i njihova farmaceutska uporaba |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| AU2022228701A1 (en) | 2021-03-05 | 2023-09-14 | Universität Basel | Compositions for the treatment of ebv associated diseases or conditions |
| JP2024511617A (ja) * | 2021-03-24 | 2024-03-14 | ユーハン・コーポレイション | 新規なインドールアミン－２，３－ジオキシゲナーゼ阻害剤、その製造方法、およびそれを含む医薬組成物 |
| WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| IL309378A (en) | 2021-06-23 | 2024-02-01 | Gilead Sciences Inc | Diacylglyercol kinase modulating compounds |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022297367B2 (en) | 2021-06-23 | 2025-04-10 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023090850A1 (en) * | 2021-11-17 | 2023-05-25 | Yuhan Corporation | Synergic combination of 2,3-dioxygenase inhibitor and immune checkpoint inhibitor for the treatment of cancer |
| WO2023122723A1 (en) | 2021-12-23 | 2023-06-29 | The Broad Institute, Inc. | Panels and methods for diagnosing and treating lung cancer |
| CN116925080B (zh) * | 2022-03-29 | 2025-12-12 | 杭州健崃生物科技有限公司 | 作为Akt蛋白激酶抑制剂的化合物及其制备方法和用途 |
| WO2024145315A1 (en) * | 2022-12-27 | 2024-07-04 | Northwestern University | Targeted protein degraders of indoleamine 2,3-dioxygenase 1 (ido1) |
| WO2025066935A1 (en) * | 2023-09-28 | 2025-04-03 | Hepaitech (Beijing) Biopharma Technology Co., Ltd. | Compounds, compositions and methods thereof |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU645681B2 (en) | 1991-05-02 | 1994-01-20 | John Wyeth & Brother Limited | Piperazine derivatives |
| DE69322707T2 (de) | 1992-07-31 | 1999-08-19 | Bristol-Myers Squibb Company | Diphenyl Oxazole-, Thiazole- und Imidazole-Derivate als Inhibitoren der Wiederaufnahme des Adenosins |
| AU666040B2 (en) | 1992-10-28 | 1996-01-25 | Bayer Aktiengesellschaft | Substituted 1-H-3-aryl-pyrrolidine-2,4-dione derivatives |
| DE4239151A1 (de) | 1992-11-20 | 1994-05-26 | Thomae Gmbh Dr K | N,N-Disubstituierte Arylcycloalkylamine, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung |
| GB9411099D0 (en) * | 1994-06-03 | 1994-07-27 | Wyeth John & Brother Ltd | Piperazine derivatives |
| DE19615232A1 (de) * | 1996-04-18 | 1997-10-23 | Merck Patent Gmbh | Neue Carbamoylderivate und deren Verwendung als 5-HT ¶1¶¶A¶-Antagonisten |
| WO1999029310A2 (en) | 1997-12-05 | 1999-06-17 | Medical College Of Georgia Research Institute, Inc. | Regulation of t cell-mediated immunity by tryptophan and its analogs |
| DE19756036A1 (de) | 1997-12-17 | 1999-06-24 | Merck Patent Gmbh | Amid- und Harnstoffderivate |
| AR015035A1 (es) | 1998-04-29 | 2001-04-11 | American Home Prod | Agentes serotonergicos, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento |
| US6632836B1 (en) | 1998-10-30 | 2003-10-14 | Merck & Co., Inc. | Carbocyclic potassium channel inhibitors |
| US6100279A (en) | 1998-11-05 | 2000-08-08 | Schering Corporation | Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom |
| CO5150225A1 (es) | 1999-03-19 | 2002-04-29 | Merck Sharp & Dohme | Derivados del tetrahidropirano y su uso como agentes terapeuticos |
| EP1212327B8 (en) | 1999-09-17 | 2004-02-25 | Abbott GmbH & Co. KG | Pyrazolopyrimidines as therapeutic agents |
| ATE282623T1 (de) * | 1999-12-22 | 2004-12-15 | Lilly Co Eli | Verfahren und verbindungen für die hemmung von mrp1 |
| SE9904738D0 (sv) * | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
| US6677336B2 (en) | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| CA2410660A1 (en) | 2000-06-01 | 2001-12-06 | Warner-Lambert Company | Cyclohexylamine derivatives as subtype selective nmda receptor antagonists |
| JP3950046B2 (ja) | 2000-09-21 | 2007-07-25 | ファイザー・プロダクツ・インク | レゾルシノール誘導体 |
| BR0211393A (pt) | 2001-07-24 | 2004-08-17 | Richter Gedeon Vegyeszet | Derivados de piperidina como antagonistas de receptor nmda |
| US20040029887A1 (en) | 2002-05-23 | 2004-02-12 | Bhatia Pramila A. | Acetamides and benzamides that are useful in treating sexual dysfunction |
| CN1744899A (zh) | 2002-12-13 | 2006-03-08 | 史密丝克莱恩比彻姆公司 | 作为ccr5拮抗剂的哌啶衍生物 |
| WO2004093871A1 (en) | 2003-03-27 | 2004-11-04 | Lankenau Institute For Medical Research | Novel methods for the treatment of cancer |
| US7598287B2 (en) | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
| JP2006522744A (ja) * | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法 |
| DE10337184A1 (de) | 2003-08-13 | 2005-03-10 | Gruenenthal Gmbh | Substituierte 3-Pyrrolidin-Indol-Derivate |
| WO2005025498A2 (en) | 2003-09-08 | 2005-03-24 | Corus Pharma | Substituted acetanilides and benzamides for the treatment of asthma and pulmonary inflammation |
| PE20050948A1 (es) | 2003-09-09 | 2005-12-16 | Japan Tobacco Inc | Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv |
| EP1716100A2 (en) | 2004-02-11 | 2006-11-02 | Pfizer, Inc. | Therapeutic amide derivatives |
| DE102004023507A1 (de) | 2004-05-10 | 2005-12-01 | Grünenthal GmbH | Substituierte Cyclohexylessigsäure-Derivate |
| DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| ES2432091T5 (es) | 2005-03-25 | 2022-03-18 | Gitr Inc | Moléculas de unión GITR y usos de las mismas |
| EP2559690B1 (en) | 2005-05-10 | 2016-03-30 | Incyte Holdings Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
| US8071768B2 (en) * | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| EP1954287B2 (en) * | 2005-10-31 | 2016-02-24 | Merck Sharp & Dohme Corp. | Cetp inhibitors |
| EP2385053B1 (en) | 2005-11-17 | 2013-10-02 | OSI Pharmaceuticals, Inc. | Intermediates for the preparation of fused bicyclic mTOR inhibitors |
| WO2007063839A1 (ja) | 2005-11-30 | 2007-06-07 | Shionogi & Co., Ltd. | シクロヘキサン誘導体 |
| DE102005061428A1 (de) | 2005-12-22 | 2007-08-16 | Grünenthal GmbH | Substituierte Cyclohexylmethyl-Derivate |
| WO2007076055A2 (en) * | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| ES2526813T3 (es) * | 2005-12-22 | 2015-01-15 | Cancer Research Technology Limited | Inhibidores de enzimas |
| CN101346361A (zh) | 2005-12-22 | 2009-01-14 | 阿斯利康(瑞典)有限公司 | 化合物 |
| WO2007095050A2 (en) | 2006-02-09 | 2007-08-23 | Incyte Corporation | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
| US20080039453A1 (en) | 2006-03-20 | 2008-02-14 | David Putman | Enantiomerically pure R-etifoxine, pharmaceutical compositions thereof and methods of their use |
| RU2478620C2 (ru) * | 2006-06-01 | 2013-04-10 | Санофи-Авентис | Спироциклические нитрилы в качестве ингибиторов протеазы |
| EP1918281A1 (en) | 2006-11-02 | 2008-05-07 | Laboratorios del Dr. Esteve S.A. | Phenylamino-substituted piperidine compounds, their preparation and use as medicaments |
| JP2010509224A (ja) | 2006-11-06 | 2010-03-25 | ニューロジェン・コーポレーション | ｃｉｓ−シクロヘキシル置換ピリミジノン誘導体 |
| WO2008075172A2 (en) | 2006-12-19 | 2008-06-26 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| US7986356B2 (en) | 2007-07-25 | 2011-07-26 | Hewlett-Packard Development Company, L.P. | System and method for determining a gamma curve of a display device |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009052319A1 (en) | 2007-10-16 | 2009-04-23 | Northeastern University | Monoacylglycerol lipase inhibitors for modulation of cannabinoid activity |
| JP5536752B2 (ja) | 2008-03-18 | 2014-07-02 | アリーナ ファーマシューティカルズ， インコーポレイテッド | プロスタサイクリン（ｐｇｉ２）受容体に関連する障害の処置に有用なｐｇｉ２受容体の調節因子 |
| BRPI0909527A2 (pt) | 2008-03-27 | 2019-09-24 | Gruenenthal Gmbh | derivados substituídos de 4-aminociclohexano |
| US20090298834A1 (en) | 2008-06-02 | 2009-12-03 | Hassan Pajouhesh | 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers |
| DK2315756T5 (en) | 2008-07-08 | 2015-08-03 | Incyte Corp | 1,2,5-oxadiazoles as inhibitors of indoleamine-2,3-dioxygenase |
| EP2149373A1 (en) * | 2008-08-01 | 2010-02-03 | Laboratorios Del. Dr. Esteve, S.A. | 5HT7 receptor ligands and compositions comprising the same |
| US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010025308A2 (en) * | 2008-08-27 | 2010-03-04 | Universtiy Of Southern California | Inhibitors of dutpase |
| EP2352732B1 (en) | 2008-12-01 | 2013-02-20 | Merck Patent GmbH | 2,5-DIAMINO-SUBSTITUTED PYRIDO[4, 3-d]PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER |
| FI4209510T3 (fi) | 2008-12-09 | 2024-03-22 | Hoffmann La Roche | Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi |
| US8541424B2 (en) | 2008-12-23 | 2013-09-24 | Abbott Laboratories | Anti-viral compounds |
| MA33128B1 (fr) * | 2009-02-17 | 2012-03-01 | Chiesi Farma Spa | Derives de triazolopyridine utilises comme inhibiteurs de la p38 map kinase |
| CA2987743A1 (en) * | 2009-03-13 | 2010-09-16 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Purine derivatives and their use as immunosuppressive agents |
| RU2595409C2 (ru) | 2009-09-03 | 2016-08-27 | Мерк Шарп И Доум Корп., | Анти-gitr-антитела |
| EP2493862B1 (en) * | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| SI2510010T1 (sl) | 2009-12-10 | 2016-02-29 | F. Hoffmann-La Roche Ag | Protitelesa, vezavna na ekstracelično domeno 4 humanega csf1r in njihova uporaba |
| CN102108078B (zh) * | 2009-12-24 | 2013-10-30 | 沈阳药科大学 | 1,4-取代酞嗪类化合物及其制备方法和用途 |
| PE20170779A1 (es) | 2010-03-04 | 2017-07-04 | Macrogenics Inc | Anticuerpos reactivos con b7-h3, fragmentos inmunologicamente activos de los mismos y usos de los mismos |
| RU2617966C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| JP2013521765A (ja) | 2010-03-05 | 2013-06-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| SI2563771T1 (sl) | 2010-04-24 | 2016-05-31 | Viamet Pharmaceuticals, Inc. | Spojine inhibitorjev metaloencimov |
| WO2011139636A1 (en) * | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small molecule inhibitors of functions of the hiv-1 matrix protein |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| US8658603B2 (en) | 2010-06-16 | 2014-02-25 | The Regents Of The University Of Michigan | Compositions and methods for inducing an immune response |
| PH12013500395B1 (en) | 2010-09-09 | 2020-10-16 | Pfizer | 4-1bb binding molecules |
| RS57324B1 (sr) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antitela i drugi molekuli koji vezuju b7-h1 i pd-1 |
| TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑 |
| EP3763741A1 (en) | 2011-11-28 | 2021-01-13 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| EP3981791A1 (en) | 2012-08-30 | 2022-04-13 | Amgen Inc. | A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor |
| SG10201906328RA (en) | 2012-08-31 | 2019-08-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| WO2014079850A1 (en) | 2012-11-23 | 2014-05-30 | F. Hoffmann-La Roche Ag | Substituted heterocyclic derivatives |
| WO2014086453A1 (en) * | 2012-12-07 | 2014-06-12 | Merck Patent Gmbh | Azaheterobicyclic compounds |
| ES2675022T3 (es) * | 2013-03-15 | 2018-07-05 | Bristol-Myers Squibb Company | Inhibidores de indolamina 2,3-dioxigenasa (IDO) |
| US12433920B2 (en) | 2013-03-29 | 2025-10-07 | Biomed Valley Discoveries, Inc. | C. novyi for the treatment of solid tumors in non-human animals |
| IL293212B2 (en) * | 2014-05-28 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Anti-GITR antibodies and methods of using them |
| WO2015188085A1 (en) | 2014-06-06 | 2015-12-10 | Flexus Biosciences, Inc. | Immunoregulatory agents |
| GB201419579D0 (en) | 2014-11-03 | 2014-12-17 | Iomet Pharma Ltd | Pharmaceutical compound |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| UY36391A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| WO2016073738A2 (en) | 2014-11-05 | 2016-05-12 | Flexus Biosciences, Inc. | Immunoregulatory agents |
-
2015
- 2015-11-04 UY UY0001036390A patent/UY36390A/es active IP Right Grant
- 2015-11-05 DK DK15857812.0T patent/DK3215153T3/da active
- 2015-11-05 TW TW104136568A patent/TWI740808B/zh active
- 2015-11-05 KR KR1020177015285A patent/KR102514378B1/ko active Active
- 2015-11-05 CN CN201580072533.3A patent/CN107427499B/zh active Active
- 2015-11-05 US US14/933,863 patent/US9643972B2/en active Active
- 2015-11-05 JP JP2017524447A patent/JP6735274B2/ja active Active
- 2015-11-05 SM SM20210163T patent/SMT202100163T1/it unknown
- 2015-11-05 SI SI201531497T patent/SI3215153T1/sl unknown
- 2015-11-05 SG SG11201702811RA patent/SG11201702811RA/en unknown
- 2015-11-05 EP EP15857812.0A patent/EP3215153B1/en active Active
- 2015-11-05 PE PE2017000807A patent/PE20171329A1/es unknown
- 2015-11-05 HU HUE15857812A patent/HUE054015T2/hu unknown
- 2015-11-05 PT PT158578120T patent/PT3215153T/pt unknown
- 2015-11-05 WO PCT/US2015/059311 patent/WO2016073770A1/en not_active Ceased
- 2015-11-05 RS RS20210198A patent/RS61457B1/sr unknown
- 2015-11-05 HR HRP20210291TT patent/HRP20210291T1/hr unknown
- 2015-11-05 US US15/524,396 patent/US20180282281A1/en not_active Abandoned
- 2015-11-05 EA EA201790992A patent/EA037286B1/ru unknown
- 2015-11-05 CA CA2964290A patent/CA2964290C/en active Active
- 2015-11-05 PL PL15857812T patent/PL3215153T3/pl unknown
- 2015-11-05 ES ES15857812T patent/ES2848978T3/es active Active
- 2015-11-05 EP EP20213702.2A patent/EP3854394A1/en active Pending
- 2015-11-05 MX MX2017005646A patent/MX385822B/es unknown
- 2015-11-05 AU AU2015342940A patent/AU2015342940B2/en active Active
- 2015-11-05 TN TN2017000164A patent/TN2017000164A1/en unknown
- 2015-11-05 PH PH1/2017/500629A patent/PH12017500629B1/en unknown
- 2015-11-05 LT LTEP15857812.0T patent/LT3215153T/lt unknown
- 2015-11-05 MY MYPI2017701576A patent/MY187510A/en unknown
-
2017
- 2017-03-27 US US15/469,707 patent/US10106546B2/en active Active
- 2017-04-18 ZA ZA2017/02724A patent/ZA201702724B/en unknown
- 2017-04-28 IL IL252009A patent/IL252009B/en active IP Right Grant
- 2017-05-05 CL CL2017001124A patent/CL2017001124A1/es unknown
- 2017-05-31 CO CONC2017/0005452A patent/CO2017005452A2/es unknown
-
2018
- 2018-09-06 US US16/123,912 patent/US10533014B2/en active Active
-
2021
- 2021-03-17 CY CY20211100225T patent/CY1123961T1/el unknown